Clinical Trial Update: First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A first-in-human study of the investigational agent 1A46 in advanced CD20/CD19-positive B-cell hematologic malignancies has been terminated; the trial was condu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• 1A46 (1A46)

Snippet

Sponsor: Chimagen Biosciences, Ltd | Conditions: Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder) | Phase 1, Phase 2 | Status: TERMINATED